Hysan Place, 37th Floor 500 Hennessy Road, Causeway Bay Hong Kong T: +852 2521 4122 F: +852 2845 9026
clearygottlieb.com |
FREEMAN CHAN SHUANG ZHAO DENISE SHIU PARTNERS
CHRIS CHURL-MIN LEE1 REGISTERED FOREIGN LAWYER
ROBERT K. WILLIAMS RAYMOND LAM COUNSEL
1 Admitted to practice in New York |
AMERICAS |
ASIA |
EUROPE & MIDDLE EAST | ||||||||||
NEW YORK SAN FRANCISCO SÃO PAULO |
SILICON VALLEY WASHINGTON, D.C. |
BEIJING HONG KONG SEOUL |
ABU DHABI BRUSSELS COLOGNE |
FRANKFURT LONDON MILAN |
PARIS ROME | |||||||
D: +852 2532 3783 szhao@cgsh.com |
September 12, 2022
Christine Westbrook
Celeste Murphy
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Re: |
Burning Rock Biotech Limited Response to the Staffs Comments on the Registration Statement on Form F-3 Submitted on August 16, 2022 CIK No. 0001792267 |
Dear Ms. Westbrook and Ms. Murphy:
On behalf of our client, Burning Rock Biotech Limited, a foreign private issuer incorporated under the laws of the Cayman Islands (the Company), we submit to the staff (the Staff) of the U.S. Securities and Exchange Commission (the SEC) this letter setting forth the Companys responses to the comments contained in the Staffs letter dated August 30, 2022 regarding the Companys Registration Statement on Form F-3 submitted to the SEC on August 16, 2022 (the Registration Statement). Concurrently with the submission of this letter, the Company is submitting a revised registration statement on Form F-3 (the Revised Registration Statement) via EDGAR.
Cleary Gottlieb Steen & Hamilton (Hong Kong) is affiliated with Cleary Gottlieb Steen & Hamilton LLP, a Limited Liability Partnership registered in New York.
Cleary Gottlieb Steen & Hamilton LLP or an affiliated entity has an office in each of the locations listed above.
Securities and Exchange Commission
September 12, 2022
Page 2 of 5
To facilitate the Staffs review, we have separately delivered to the Staff today five courtesy copies of the Revised Registration Statement, marked to show changes to the Registration Statement.
The Staffs comments are repeated below in bold and are followed by the Companys responses. We have included page references in the Revised Registration Statement where the language addressing a particular comment appears. Capitalized terms used but not otherwise defined herein have the meanings set forth in the Revised Registration Statement.
* * * *
2
Securities and Exchange Commission
September 12, 2022
Page 3 of 5
Cover page
1. | We note the following disclosure: Nevertheless, cash transfers have been made to date between Burning Rock Biotech Limited, our subsidiaries and the VIEs. Please revise here and throughout the registration statement to make clear that such transfers have been made in one direction only and in the direction to the VIE. |
The Company has revised the disclosure on cover page and page 16 of the Revised Registration Statement in response to the Staffs comment.
About this Prospectus, page 1
2. | With regard to the definition of China or the PRC, please revise to clarify that legal and operational risks associated with operating in China also apply to your operations in Hong Kong. |
The Company has revised the disclosure on page 1 of the Revised Registration Statement in response to the Staffs comment.
Risks Relating to Doing Business in the PRC
If the U.S. Public Company Accounting Oversight Board, or the PCAOB, is unable to inspect our auditors...., page 15
3. | Please update your discussion of the Holding Foreign Companies Accountable Act by disclosing that on August 26, 2022, the Public Company Accounting Oversight Board (PCAOB) signed a statement of Protocol with the China Securities Regulatory Commission and the Ministry of Finance of the Peoples Republic of China, taking the first step toward opening access for the PCAOB to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong. |
The Company has revised the disclosure on the cover page and pages 18 and 27 of the Revised Registration Statement.
Risks Relating to Hong Kong, page 28
4. | Please revise your discussion of the principle of one country, two systems to clarify that China could determine to treat any cash located in Hong Kong as subject to the same distribution rules as Mainland China and therefore subject to the same risks. |
The Company has revised the disclosure on page 28 of the Revised Registration Statement in response to the Staffs comment.
General
5. | Please ensure that you reflect revisions made in response to comments on your registration statement in future Exchange Act reports. |
3
Securities and Exchange Commission
September 12, 2022
Page 4 of 5
The Staffs comment is duly noted. The Company will include the additional and revised disclosure made in response to the Staffs comments on its registration statement in its future Exchange Act reports where relevant.
4
Securities and Exchange Commission
September 12, 2022
Page 5 of 5
If you have any questions regarding the Registration Statement, please contact the undersigned by phone at +852-2532-3783 or via e-mail at szhao@cgsh.com, or Leo Li, the chief financial officer of Burning Rock Biotech Limited, by telephone at +86-185-0164-1666 or via e-mail at leo.li@brbiotech.com, or Chris Yin, the partner at Ernst & Young Hua Ming LLP, by telephone at +86-20-2881-2888 or via email at Chris.Yin@cn.ey.com. Ernst & Young Hua Ming LLP is the independent registered public accounting firm of the Company.
Very truly yours, | ||
CLEARY GOTTLIEB STEEN & HAMILTON LLP | ||
By: | /s/ Shuang ZHAO | |
Shuang ZHAO, a Partner |
cc: | Leo Li, Chief Financial Officer, Burning Rock Biotech Limited |
Chris Yin, Partner, Ernst & Young Hua Ming LLP
5